DrugRisk Center Announces Addition of Safety and Litigation Updates for Pradaxa

Share Article

The Drug Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

pradaxa lawsuit
DrugRisk also includes information regarding adverse reports sent to the FDA for many prescription drugs. To date, the agency’s FAERS tracking system has received more than 22,000 reports of complications among patients taking Pradaxa.

The online prescription drug resource center DrugRisk has expanded its comprehensive database of popular medications to include FDA announcements and litigation news regarding the blood thinner Pradaxa.

“The goal of DrugRisk is to improve patient safety through education of the latest prescription drug warnings, recalls, studies and litigation. Due to the popularity of Pradaxa, we felt it necessary to give consumers the most up-to-date resources available,” said DrugRisk representative Ryan Mayer.

Among the information offered is disagreement between health experts on the safety of Pradaxa and its relation to dangerous or fatal internal bleeding. Last month, the FDA updated its warnings to say that, for now, testing shows Pradaxa carries the same risks as warfarin and Coumadin.* However, the New York Times reported doctors’ concerns the same day that Pradaxa led all other medications for adverse reports and currently has no antidote for internal bleeding.**

DrugRisk also includes information regarding adverse reports sent to the FDA for many prescription drugs. To date, the agency’s FAERS tracking system has received more than 22,000 reports of complications among patients taking Pradaxa.***

Most common among these were 6497 gastrointestinal side effects, 4910 gastrointestinal hemorrhages (bleeding) and 2941 central nervous system or cranial hemorrhaging problems. There were also 842 deaths attributed to the drug.

DrugRisk has learned that the number of patients filing a Pradaxa lawsuit claiming internal bleeding has risen 50% since September.**** Also, the cases have been moved to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*fda.gov/Drugs/DrugSafety/ucm326580.htm
**nytimes.com/2012/11/03/business/a-rising-anti-stroke-drug-is-tied-to-risk-of-bleeding-deaths.html
***drugcite.com/?q=pradaxa
****jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets-By-District-November-2012.pdf

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
DrugRisk
888-415-1859
Email >
Visit website